Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 16/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5432319 | 0.71 | GRM1 (0.42) | GRM1GRM5 | |
| SCHEMBL22488037 | 0.68 | HPGD (0.39) | XDHHCAR1GRM1KDM4E | |
| SCHEMBL5429761 | 0.68 | POLB (0.47) | XDHGRM1GRM5 | |
| SCHEMBL7987439 | 0.67 | CNOT7 (0.43) | MEN1KMT2ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL22487747 | 0.67 | XDH (0.42) | SMN1; SMN2LMNAXDHHCAR1GRM1 | |
| SCHEMBL22487919 | 0.66 | GRM1 (0.35) | XDHHCAR1GRM1GRM5KDM4E | |
| SCHEMBL22487927 | 0.66 | GSK3B (0.41) | XDHHCAR1GRM1GRM5 | |
| SCHEMBL4370028 | 0.64 | ADORA1 (0.41) | — | |
| SCHEMBL5437225 | 0.64 | SMN1; SMN2 (0.48) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL1993929 | 0.63 | ADORA2A (0.40) | RAB9ASMN1; SMN2LMNAXDHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | MEN1 4674/4885NPC1 1077/4885RAB9A 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.